Cited by 493Adenosine and Purinergic SignalingInflammasome and immune disordersImmune Response and Inflammation

Liaisons dangereuses: P2X7 and the inflammasome

Di Virgilio, Francesco·2007·Trends in Pharmacological Sciences

Abstract

Inflammation is initiated by specific pathogen constituents, in addition to intrinsic host molecules that are released by injured or dying cells. Among such host endogenous pro-inflammatory factors, nucleotides (mainly ATP) are attracting increasing interest for their potential as natural adjuvants. Extracellular ATP stimulates a family of receptors, named P2, one of which, P2X(7), is a potent mediator of interleukin (IL)-1beta and IL-18 processing and release. The mechanism and physiological significance of this unusual pro-inflammatory activity have long remained elusive. Recent data unveiling the structure and function of a novel caspase-activating platform, the inflammasome, shed light on P2X(7) receptor coupling to IL-1beta release, and suggest a fascinating scenario for the initiation and amplification of the innate immune response. Here, I outline the intriguing links between the P2X(7) receptor and the NALP3 inflammasome, review recent evidence showing that this receptor is a potent activator of this multimolecular platform and discuss implications for pathogen-immune cell interaction and for anti-inflammatory drug development.

Integrity signals

Registry

Crossref · 10.1016/j.tips.2007.07.002

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Polynucleotides and oligonucleotides from degrading DNA or RNA can act on TLR3, TLR7, TLR8, or TLR9 and on intracellular receptors RIG1, MDA5, or LGP2, while ATP and its degradation products may activate or inhibit distinct classes of purinergic receptors.

    “Polynucleotides and oligonucleotides derived from degrading DNA or RNA can act on TLR3, TLR7, TLR8, or TLR9 as well as on intracellular receptors including RIG1, MDA5, or LGP2, while ATP and its degradation products may activate or inhibit distinct classes of purinergic receptors 45,108,109.”

    From Immunogenic and tolerogenic cell death (2009) · cites this paper as [109]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Di Virgilio, F.
Venue
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Published
2007-09
Volume
28
Issue
9
Pages
465-472
ISSN
0165-6147 (ISSN-L)
OpenAlex
W1495057561
Cited by
493
References
73
Citations by year
2026: 9 · 2025: 7 · 2024: 20 · 2023: 17 · 2022: 18 · 2021: 18 · 2020: 22 · 2019: 25 · 2018: 27 · 2017: 21 · 2016: 26 · 2015: 41 · 2014: 35 · 2013: 41 · 2012: 45
FWCI
2.06
Type
journal article
Language
en
Open access
closed
Locations
  • Trends in Pharmacological Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Keywords
P2X7 receptor, NLRP3 inflammasome, extracellular ATP, interleukin-1β processing, IL-18, caspase activation, innate immunity, host-pathogen interaction, anti-inflammatory drug development
MeSH terms
Adenosine Triphosphate, Animals, Carrier Proteins, Humans, Inflammation, Connexins, Receptors, Purinergic P2, Inflammation Mediators, Caspases, Nuclear Matrix-Associated Proteins, Interleukin-1beta, Receptors, Purinergic P2X7

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review